



(Use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

Complete if Known

| | |
|-------------------------------|-------------------------------|
| Application Number | 09/875,076 |
| Filing Date | 6 June 2001 |
| First Named Inventor | Chen W. Liaw, et al. |
| Art Unit | 1646 |
| Examiner Name | MERTZ, Prema Maria |
| Attorney Docket Number | AREN-0239 (11 US9 DIV) |

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Prima Mente

Date Considered

9/28/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08B(07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2

of 2

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 09/875,076 |
| Filing Date | 6 June 2001 |
| First Named Inventor | Chen W. Liaw, et al. |
| Art Unit | 1646 |
| Examiner Name | MERTZ, Prema Maria |
| Attorney Docket Number | AREN-0239 (11.US9.DIV) |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| PM | IA | BLASZCZYK, J., "Motor Deficiency in Parkinson's Disease," <i>Acta Neurobiol. Exp.</i> (1998) 58:79-93. | |
| | IB | BROUN, P., et al., "Catalytic Plasticity of Fatty Acid Modification Enzymes Underlying Chemical Diversity of Plant Lipids," <i>Science</i> (1998) 282: 1315-1317. | |
| | IC | FEHMANN, H., "Cell and Molecular Biology of the Incretin Hormones Glucagon-Like Peptide-I and Glucose-Dependent Insulin Releasing Polypeptide," <i>Endocrine Reviews</i> (1995) 16(3):390-410. | |
| | ID | LEURS, R., et al., "Agonist-independent Regulation of Constitutively Active G-protein-coupled Receptors," <i>TIBS</i> (1998) 23:418-422. | |
| | IE | MURDOCH, C., et al., "Chemokine Receptors and Their Role in Inflammation and Infectious Diseases," <i>Blood</i> (2000) 95:3032-3043. | |
| | IF | NG, D., et al., "Point Mutation in the Second Phosphatase Domain of CD45 Abrogates Tyrosine Phosphatase Activity," <i>Biochemical and Biophysical Research Communications</i> (1995) 206 (1): 302-309. | |
| | IG | PAUWELS, P., et al., "Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors," <i>Molecular Neurobiology</i> (1998) 17:109-135. | |
| | IH | PROBST, W., et al., "Sequence Alignment of the G-Protein Coupled Receptor Superfamily," <i>DNA and Cell Biology</i> (1992) 11(1):1-20. | |
| | II | SONNHAMMER, E., "A Hidden Markov Model for Predicting Transmembrane Helices in Protein Sequences," in J. Glasgow, et al., eds., <i>Proc. Sixth Int. Conf. on Intelligent Systems for Molecular Biology</i> , pp. 175-182 (AAAI Press, 1998). | |
| | IJ | THORENS, B., "Expression Cloning of the Pancreatic β Cell Receptor for the Gluco-incretin Hormone Glucagon-like Peptide 1," <i>Proc. Natl. Acad. Sci. Cell Biology</i> (1992) 89:8641-8645. | |
| ✓ | IK | WATSON, S., <i>The G-Protein Linked Receptor FactsBook</i> , pp. 2: 223-230, (Academic Press, 1994). | |

Examiner
Signature

Prema Mertz

Date
Considered

9/28/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.